RGNX - Regenxbio Inc logo

RGNX

Regenxbio Inc

Regenxbio Inc. develops gene therapies using its NAV Technology Platform to deliver functional genes for genetic disorders. Its pipeline includes treatments for conditions like wet age-related macular degeneration and Duchenne muscular dystrophy.

⚕️ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 10 years ago $949today

Score Overview

1 Year
Score
Net Growth-1.32%
Net TrendShrank
Net Income Consistency
Rev Growth2.37%
Rev TrendGrew
Revenue Consistency
5 Years
Score3.3
Net Growth-253.65%
Net Trend60%
Net Income Consistency
Rev Growth-62.90%
Rev Trend40%
Revenue Consistency
10 Years
Score
Net Growth-211.96%
Net Trend50%
Net Income Consistency
Rev Growth38x
Rev Trend60%
Revenue Consistency
All Time
Score
Net Growth-6x
Net Trend45%
Net Income Consistency
Rev Growth22x
Rev Trend55%
Revenue Consistency

See the full market ranking →

Regenxbio Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 154M to $ 170M and net income went from -$ 111M to -$ 193M. Revenue increased in 2 of those 5 years; net income in 3.

Across Regenxbio Inc's full reported history, from 2015 to 2025, revenue grew from $ 7M to $ 170M and net income went from -$ 22M to -$ 193M. Revenue increased in 55% of the years measured; net income in 45%.

Regenxbio Inc currently holds a 5-year HDB Score of 3.3 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 10.91
1 Year2025-08-12
$ 8.1034.69%
5 Years2021-08-12
$ 31.41-65.27%
10 Years2016-08-12
$ 11.50-5.13%
All Time2015-09-17
$ 30.45-64.17%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 174M-$ 196M$ 105M
2025$ 170M-$ 193M$ 230M
2024$ 83M-$ 227M$ 234M
2023$ 90M-$ 263M$ 275M
2022$ 112M-$ 280M$ 364M
2021$ 470M$ 127M$ 457M
2020$ 154M-$ 111M$ 475M
2019$ 35M-$ 94M$ 296M
2018$ 218M$ 99M$ 319M
2017$ 10M-$ 73M$ 160M
2016$ 4M-$ 62M$ 89M
IPO2015$ 7M-$ 22M$ 114M

Explore beyond RGNX

You're looking at Regenxbio Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies